Franklin Biotechnology Price To Book vs. Net Asset

FRBRX Fund  USD 129.58  10.95  7.79%   
Based on the key profitability measurements obtained from Franklin Biotechnology's financial statements, Franklin Biotechnology Discovery may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Franklin Biotechnology's ability to earn profits and add value for shareholders.
For Franklin Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Franklin Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Franklin Biotechnology Discovery utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Franklin Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Franklin Biotechnology Discovery over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities.
Please note, there is a significant difference between Franklin Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Franklin Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Franklin Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Franklin Biotechnology Net Asset vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Franklin Biotechnology's current stock value. Our valuation model uses many indicators to compare Franklin Biotechnology value to that of its competitors to determine the firm's financial worth.
Franklin Biotechnology Discovery is one of the top funds in price to book among similar funds. It also is one of the top funds in net asset among similar funds making up about  318,449,851  of Net Asset per Price To Book. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Franklin Biotechnology's earnings, one of the primary drivers of an investment's value.

Franklin Net Asset vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Franklin Biotechnology

P/B

 = 

MV Per Share

BV Per Share

 = 
4.46 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Franklin Biotechnology

Net Asset

 = 

Current Market Value

-

Current Liabilities

 = 
1.42 B
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.

Franklin Net Asset Comparison

Franklin Biotechnology is currently under evaluation in net asset among similar funds.

Franklin Biotechnology Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Franklin Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Franklin Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Franklin Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Franklin Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Under normal market conditions, the fund invests at least 80 percent of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20 percent of its net assets in equity or debt securities of any type of issuer. It is non-diversified.

Franklin Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Franklin Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Franklin Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Franklin Biotechnology's important profitability drivers and their relationship over time.

Use Franklin Biotechnology in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Franklin Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Franklin Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Franklin Biotechnology Pair Trading

Franklin Biotechnology Discovery Pair Trading Analysis

The ability to find closely correlated positions to Franklin Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Franklin Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Franklin Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Franklin Biotechnology Discovery to buy it.
The correlation of Franklin Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Franklin Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Franklin Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Franklin Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Franklin Biotechnology position

In addition to having Franklin Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cash Cows Thematic Idea Now

Cash Cows
Cash Cows Theme
Entities with stable and reliable earnings or profits, which allows them to pay consistent dividends to their shareholders. The Cash Cows theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cash Cows Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Franklin Mutual Fund

To fully project Franklin Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Franklin Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Franklin Biotechnology's income statement, its balance sheet, and the statement of cash flows.
Potential Franklin Biotechnology investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Franklin Biotechnology investors may work on each financial statement separately, they are all related. The changes in Franklin Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Franklin Biotechnology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years